Osteoprotegerin (OPG) is a member of the tumor necrosis factor superfamily. It is a soluble "decoy" receptor for tumor necrosis factor-related apoptosis-inducing ligand and ligand of the receptor activator of NF-B. As such, OPG inhibits osteoclast activity and regulates the immune system. Human milk is a complex biologic fluid that supplies nutritional and protective factors to the breast-fed infant. In the present study, human milk samples at various times postpartum were assessed for the presence of OPG. Using biochemical as well as immunologic and biologic techniques we showed that human milk contains OPG at a level that is 1000-fold higher than that found in normal human serum. We observed that human breast milk cells and the human mammary epithelial cell line MCF-7 express OPG, indicating that both cell types are possible sources of milk OPG in vivo. In vitro studies demonstrated that milk OPG is biologically active and suggested that it may contribute to the antiresorptive activity of milk on bone, as well as tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of T cell proliferation. OPG-like activity was also observed in bovine colostrum and milk. Furthermore, we were able to detect human OPG in the sera of rats gavaged with human milk. We discuss the relevance of our findings for the breast-fed infant and for the prevention of immune and bone disorders. Members of the tumor necrosis factor (TNF) and TNF receptor superfamilies are instrumental in the regulation of immune homeostasis in multiple sites of the body and as such are the main targets for therapies against a range of human diseases. The receptor activator of NF-B (RANK) and its ligand (RANKL) are among the most recently described molecules of the TNF family. They have intrinsic roles to play in the development of immune responses by modulating the survival of dendritic cells and their antigen presentation to T cells (1, 2) . The absence of peripheral and mesenteric lymph nodes in animals that lack either of these genes strongly suggests that signaling through these molecules is a prerequisite for normal development of these lymphoid organs (3, 4) . Furthermore, both molecules are recognized as key regulators in bone remodeling and the development and activation of osteoclasts (5) .
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor, is a naturally occurring soluble member of the TNF receptor family (6 -8) that functions as a secreted "decoy" receptor for RANKL (5) and for at least one other TNF family member, TNF-related apoptosis-inducing ligand (TRAIL) (9) , an inducer of apoptosis for a variety of cell lines (10) . It has been shown that OPG inhibits osteoclastogenesis in vitro, prevents osteoporosis (11) , and regulates B cell maturation and the development of efficient antibody responses (12) . OPG therefore represents a natural regulator of a variety of cellular processes in bone metabolism and in the immune system.
The neonatal period is particularly critical for the processes governing normal bone remodeling and the development of immune responses. Osteogenesis is a dynamic process that exceeds resorption during the neonatal period and thereby ensures that bone formation parallels the rapid changes in size lyzed Signal Amplification System (Dako). Cells were counterstained with Mayer's hematoxylin.
RT-PCR amplification. DNase-treated RNA was reversetranscribed with MuLV reverse transcriptase (RT) (PerkinElmer, Heunenberg, Switzerland) following the manufacturer's instructions. RT products were amplified with Gold DNA polymerase (Perkin-Elmer) on a thermocycler (Biolabo, Scientific Instruments, Chatel St Denis, Switzerland). Primers for OPG were as follows: 5'-ACTAGTTATAAGCAGCT-TATTTTTACTG-3' and 5'-GGAGGCATTCTTCAGGTTT-GCTG-3'; RANKL: 5'-AGCTGCGAAGGGGCACATGA-3' and 5'-ACTGGATCCGGATCAGGATG-3'; TACE: 5'-CCA-TGAAGTGTTCCGATAGAT GTC-3' and 5'-ACCTGAAGA-GCTTGTTCATCGAG-3'; and ␤-actin: 5'-CGATTTCCCG-CTCGGCCGTGGTGGTGAAGC-3' and 5'-GGCGACGAGG-CCCAGAGCAAGAGAGGCATC-3'. cDNA was amplified starting with 95°C for 10 min, followed by 35 cycles of 94°C for 45 s, 60°C for 60 s, and 72°C for 90 s, and a final cycle of 72°C for 7 min. The size of the PCR products for OPG, TACE, RANKL, and ␤-actin were 603, 190, 329, and 460 bp, respectively. A full-length OPG cDNA (1174 bp) was generated by RT-PCR using 5'-CCGGCCTCTTCGGCCGCCAAGC-GAGAAACGTTTCCTCCAAAGTACC-3' and 5'-ACTAGT-TATAAGCAGCTTATTTTTACTG-3' primers. The PCR product was gel-purified and ligated into pCR-XL-TOPO (Invitrogen, Basel, Switzerland).
Western blot analysis. Skimmed human milk (1:5), normal human serum (1:50), and rOPG (20 ng/lane; R&D Systems), separated by 10% or 4% to 20% SDS-PAGE under reducing or nonreducing conditions, were transferred to nitrocellulose (BioRad, Glattbrugg, Switzerland). OPG was identified by incubation with the anti-OPG MAb, IMG-103 (2 g/mL; Imgenex, AMS Biotechnology, Lugano, Switzerland) using WesternBreeze Chromogenic Detection kit (Invitrogen). Prestained protein markers were used as M r standards (BioRad).
ELISA. OPG and sRANKL concentrations were determined by specific ELISA kits (Immunodiagnostik, Bensheim, Germany) with a detection limit of~0.14 pM and 0.4 pM, respectively.
FACS analysis. Cell suspensions of MCF-7 were incubated at 4°C for 30 min with FITC-conjugated mouse anti-TACE MAb (R&D Systems) or an isotype-matched Ab (IgG1; Becton-Dickinson, Heidelberg, Germany). Cells were analyzed on a FACScan flow cytometer (Becton-Dickinson) using CellQuest analysis software.
Cell viability assay. Jurkat cells (5 ϫ 10 4 cells/well) were cultured in the presence of recombinant TRAIL (0 to 20 ng/mL; Alexis) and enhancer (2 g/mL; Alexis). Recombinant OPG (50 ng/mL; R&D Systems) or human milk fractions (1:20) were added to specific wells with or without MAB805, an anti-OPG MAb (20 g/mL; R&D Systems), or its isotypematched control (IgG1; Sigma Chemical Co.). Plates were incubated for a total of 16 h, with cell proliferation being measured by adding 3 H-TdR (1 Ci/well) during the last 6 h. Bone pit resorption analysis. Bone cells were prepared from long bones of 10-d-old New-Zealand rabbits (Elevages Scientifiques des Dombes, France) as previously described (16) .
Briefly, bones were minced in ␣-MEM (Sigma Chemical Co.), and the cells released by vigorous vortexing were collected in the supernatant after allowing a short sedimentation. The osteoclast-rich preparation was seeded into plates containing cortical bone slices in ␣-MEM supplemented with 1% FCS. After 80 min, nonadherent cells were removed and fresh medium was added. Recombinant OPG (40 ng/mL), human milk (1:20), and bovine colostrum or milk (1:25) was added to specific wells, in the presence or absence of recombinant RANKL (100 ng/mL; Alexis). After 72 h of incubation at 37°C, bone slices were stained with toluidine blue-1% borate, and the pit area was measured using a computer analysis system according to stereologic principles.
Gavage of rats. Suckling 5-d-old Sprague Dawley rat pups (Iffa-Credo, France) were gavaged with 0.3 mL of human milk (n ϭ 10) or a rat milk substitute (17) (n ϭ 10) or were kept with their mothers (n ϭ 10). Blood samples were collected from five rats per group after 1.5 h and from the remaining five animals in each group after 4 h.
Statistical analysis. Means were compared using one-way ANOVA, and multiple comparison tests were computed using Fisher's least significant difference on a 5% significant level. Two means differing by more than the least significant difference are significantly different (␣ ϭ 5%).
RESULTS

Characterization of OPG in human milk.
Samples of human milk obtained from healthy lactating mothers who delivered at term (37-42 wk; n ϭ 87) or preterm (Ͻ37 wk; n ϭ 6) were examined for their levels of OPG using a specific ELISA (Fig. 1A) . In human milk from mothers who delivered at term, the range of OPG concentration in colostrum (0 -5 d; n ϭ 23) was 2.8 to 40.6 nM (mean, 14.4 nM), in transitional milk (6 -30 d; n ϭ 41) was 0.7 to 39.9 nM (mean, 9.3 nM), and in mature milk (Ͼ30 d; n ϭ 23) was 2.9 to 32.1 nM (mean, 22.1 nM) (Fig. 1A) . There was no significant correlation between the OPG concentration and the duration of lactation. In human milk (0 -22 d; n ϭ 3) from mothers who delivered preterm, the range of OPG concentration was 1.7 to 17.8 nM (mean, 7.0 nM). Irrespective of the time in lactation, mean OPG levels in human milk samples were much higher than those observed in the serum during pregnancy (5.08 Ϯ 1.60 pM) or lactation (at 3 and 6 mo postpartum; mean, 4.03 Ϯ 1.08 pM; Table 1 ) or in normal serum (4.0 Ϯ 1.0 pM).
The nature of OPG in human milk samples collected up to day 71 postpartum was examined by immunoblot analysis (Fig.  1B) . The apparent M r of milk OPG was~58 kD under reducing conditions and~190 kD under nonreducing conditions. No monomeric form of OPG with a mass of~58 kD was detected under nonreducing conditions. Under reducing conditions, the OPG migrated even slower than the expected homodimeric form. Similar results were obtained when normal human serum was used, although additional minor bands were observed. Of note, the rOPG used as positive control was generated as a chimeric protein and therefore has an apparent M r of~80 kD under reducing conditions. In milk fractions, OPG was detected in skimmed milk, cream, and whey but not in casein fractions (data not shown).
Mammary epithelial cells and milk cells are potential sources of milk OPG. To identify the cellular source of milk OPG, we investigated whether OPG mRNA was expressed in the human mammary epithelial cell line MCF-7 and/or in HBMC. A single band of the expected size (603 bp) was detected in each sample ( Fig. 2A) . Furthermore, we cloned the full-length OPG cDNA product obtained from HBMC and found that this coded for the mature form of OPG. We then assessed the protein expression by HBMC and MCF-7 cells. Immunocytochemical staining with a specific anti-OPG antibody revealed the expression in epithelial cells and macrophages of HBMC (Fig. 2B) . Furthermore, specific ELISA revealed the presence of OPG protein in the culture supernatant of MCF-7 (Fig. 3) . The modulatory effects of factors known to regulate OPG expression [see review (18) and Refs. (19, 20) ] were studied in MCF-7 cells (Fig. 3) . Treatment of the cells for 48 h in the presence of 17␤-estradiol, 1,25-dihydroxyvitamin D 3 , PTH (all 10 Ϫ7 M), IL-18, or TGF-␤ (5 ng/mL) had no effect on OPG expression by MCF-7. In contrast, treatment with TNF-␣ (10 ng/mL), IL-1␤ (25 U/mL), or leptin (2 g/mL) induced, respectively, an~10-fold, 5-fold, and 2-to 3-fold increase in OPG when compared with untreated cells.
Milk OPG blocked TRAIL-induced inhibition of Jurkat cell proliferation. To test whether milk OPG was biologically active, we examined its capacity to modulate TRAIL-induced apoptosis of the Jurkat cell line (9) . More specific, we measured its effect on the incorporation of 3 H thymidine by Jurkat cells cultured in the presence of increasing doses of TRAIL (Fig. 4) . As expected, rOPG specifically reversed the TRAILinduced inhibition of Jurkat cell proliferation (Fig. 4A) . Exposure of Jurkat cells to either skimmed human milk or sweet whey also inhibited the effect of TRAIL on Jurkat cell proliferation (Fig. 4B) . Anti-OPG MAb but not its isotype-matched control reversed the effect of the milk fractions as well as that of the rOPG. The casein fraction, which does not contain OPG, had no effect on TRAIL-induced inhibition of Jurkat cell proliferation.
Milk OPG inhibits osteoclast-mediated bone resorption in vitro. Milk OPG was also tested for its ability to suppress osteoclast-mediated bone resorption in an in vitro rabbit pit assay. Bone-resorbing activity was significantly decreased by human milk (77%), bovine colostrum (day 2 postpartum; 52%), and bovine milk (day 10 postpartum; 50%), as well as by rOPG (44% inhibition; Fig. 5 ). The addition of recombinant RANKL had no effect when given alone (9% inhibition), but it significantly decreased the inhibition of bone-resorbing activity mediated by rOPG from 44% to 4%, that mediated by human milk from 77% to 54%, that of bovine colostrum from 52% to 29%, and that of bovine milk from 50% to 27%. Indeed, two levels of inhibition differing by Ͼ15% were considered significantly different (␣ ϭ 5%). That RANKL only partially reversed the effects of milk samples suggests that the milk contains antiresorptive agents besides OPG.
Milk OPG crosses the gastrointestinal tract. For examining whether milk-derived OPG reaches extraintestinal tissues, rat pups were gavaged with human milk and their blood was subsequently examined for the presence of OPG using an ELISA specific for human OPG. A small but significant amount of OPG was detected after 1.5 h (4.20 and 9.37 pM) or 4 h (2.85 and 3.95 pM) in the plasma of some pups that were gavaged with human milk. As expected, human milk-derived OPG was not detected in the blood of rats that received an artificial milk substitute or in that of suckling pups (Table 2) . This preliminary experiment suggests that milk-derived OPG Expression of RANKL and TNF-␣-converting enzyme by MCF-7 cells and human milk cells. Because the balance between OPG and RANKL critically determines biologic outcome, we also investigated the expression of the latter and of the TNF-␣-converting enzyme (TACE), which is involved in release of RANKL from the plasma membrane (21) . Both MCF-7 and HBMC constitutively expressed the mRNAs for RANKL and TACE (expected size band 329 bp and 190 bp, respectively; Fig. 6A ). FACS analysis demonstrated the expression of TACE protein (Fig. 6B) but not of RANKL (data not shown) on the surface of MCF-7 cells. Furthermore, using a specific ELISA, we were unable to detect soluble RANKL in either the cell culture supernatant of MCF-7 or in human milk.
DISCUSSION
The protein components of human milk contribute to many of the important nutritional and physiologic functions associated with breast-feeding. Among these proteins are secretory IgA, lactoferrin, lysozyme, cytokines that participate in host defense mechanisms, and an array of growth factors such as IGF, TGF-␤, and other factors that play an important role in osteogenesis. Here, we provide direct evidence for the presence of a large amount of active OPG in human milk. OPG is present in human milk samples at different times during lactation in concentrations that are up to 1000-fold higher than that found in normal human serum. No significant differences were observed between milk collected from mothers of premature versus term infants.
OPG has been described as both a monomer and a homodimer (6, 7, 22) . We found that the OPG protein in both human milk and human normal serum seemed to be predominantly in a disulfide-linked trimeric or tetrameric form, suggesting that the molecule might exhibit unusual disulfide bonding and/or glycosylation. Our finding on the serum is in contrast to the report of Yano et al. (23) , which showed that OPG circulates predominantly in a monomeric form. The reason for this discrepancy is unknown. However, it is possible that in the Japanese study, there was a conversion of polymeric OPG into monomeric OPG by protease(s) involved in blood coagulation or by fibrinolysis during the preparation of the blood samples. ND, not detectable. * Neonatal rats were gavaged as described in "Methods." Blood samples were collected from five rats per group after 1.5 h and from the remaining five animals in each group after 4 h. † The total number of samples tested at each time point and those with detectable levels of OPG are indicated.
‡ Data represent OPG levels (pM) in blood samples tested by ELISA.
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Both mammary gland epithelial cells and HBMC are potential sources of milk OPG. In agreement with a recent report (15), we found that OPG protein is secreted by cultured human mammary gland epithelial cells, MCF-7. However, we also found that HBMC expressed mRNA for OPG. The HBMC population contains epithelial cells, phagocytes, and lymphocytes. Phagocytes predominate early in lactation, but mammary epithelial cells shed into milk are the predominant cell type after the second month of lactation (24) . We found that milk epithelial cells and phagocytes but not milk lymphocytes expressed OPG. The lack of OPG expression by milk lymphocytes is coherent with the observation that OPG is not expressed in peripheral blood lymphocytes (13) . It is interesting that it has been reported that milk epithelial cells exhibit characteristics of viable, differentiated alveolar epithelial cells (25, 26) , suggesting that these cells could be regulated to produce and secrete OPG in situ.
We have considered that the high concentration of OPG in human milk compared with human serum may be a consequence of an increased OPG in maternal blood finding its way into the milk. To date, the cellular source of circulating OPG is not known, and the mechanisms that regulate the levels in serum have not been described. Nevertheless, it has been reported that the concentration of circulating OPG markedly increases in the mouse during pregnancy and that it may serve to protect against excess bone resorption prepartum (27) . Recently, a study in humans also showed that the concentrations of serum OPG in mothers steadily increases during pregnancy. However, the levels immediately before delivery were onlỹ 2.5 times higher than those in nonpregnant, nonpuerperal women and fell rapidly after delivery (28) . In our study, serum OPG concentrations in mothers at 8 mo gestation and during lactation were not significantly different from those reported for normal human donors. Thus, the high levels in milk may be due to increased local production by the mammary gland and/or the milk cellular compartment. A number of factors, including hormones, growth factors, and inflammatory mediators, have the capacity to up-regulate OPG expression in human bone marrow stromal cells and osteoblasts [for review, see Ref. (18)]. Of these, TNF-␣, IL-1␤, and leptin have been found in human colostrum and milk (29, 30) . Furthermore, it has been shown that TNF, which is expressed by rat mammary epithelial cells in a developmentally regulated manner, is a physiologically significant regulator of mammary gland development and of milk protein gene expression (31) . We describe herein that treatment of mammary epithelial cells with these cytokines resulted in increased OPG expression. These findings suggest that in vivo, TNF, IL-1␤, and/or the leptin present in human milk or mammary tissue may regulate production of OPG by mammary epithelial cells.
Given the known effects of OPG on bone remodeling, we tested the capacity of milk OPG to inhibit the activity of mature osteoclasts in an in vitro bone resorption assay. Human milk and bovine colostrum and milk inhibited osteoclast activity in a manner that was partially reversed by the addition of soluble RANKL. It is clear that milk might contain components, other than OPG, that can down-regulate osteoclast activity. Because all genetic and functional experiments indicate that the balance between RANKL-OPG regulates development and activation of osteoclasts and bone metabolism (6, 32), we considered that human milk may also contain a soluble form of RANKL. In contrast to a previous report (15) , we found that MCF-7 cells express specific mRNA for RANKL, but we were unable to detect any protein expression at the cell surface. Consequently, we assessed the expression of the metalloprotease-disintegrin TACE, which is known to play a role in the shedding of RANKL from the plasma membrane (21) . Although, MCF-7 constitutively expressed TACE, we failed to detect RANKL in either the cell culture supernatant or milk samples. This may be due to insufficient sensitivity of the ELISA test that we used, and it is also feasible that the substantial amounts of OPG present in both fluids may bind any soluble RANKL present and thereby reduce the amount of "free" RANKL available for detection.
In addition to the regulatory effects of the RANKL/RANK/ OPG system on bone remodeling, a number of studies have highlighted the involvement of this system in immune responses. Binding of RANKL to RANK augments dendritic cell survival, enhances the stimulatory capacity of dendritic cells, and modulates activated T cells (2-4, 33) . Furthermore, OPG is critically involved in B cell maturation and the generation of efficient antibody responses (12) . An additional role of OPG in immune responses is related to binding to its ligand TRAIL. Although the in vivo role of TRAIL remains to be determined, it is a potent activator of apoptosis in certain cells after binding to its receptors (34) . Recently, it was reported that apoptosis mediated by TRAIL is critical in determining the fate of differentiating T helper cells, Th1 cells being more sensitive to TRAIL-induced apoptosis than Th2 cells (35) . Certainly, milk OPG interacted with TRAIL in our model of TRAIL-induced inhibition of Jurkat cell proliferation. It follows, therefore, that milk OPG could influence immune homeostasis by regulating the Th1/Th2 balance.
The functions of many of the bioactive proteins in milk remain to be elucidated, but it is likely that certain of them influence both the function of the mammary gland and the growth and development of various neonatal tissues. In addition to their role in bone homeostasis and immunobiology, RANK-RANKL interactions are critical for the development of the lactating mammary gland during pregnancy and for the expression of the ␤-casein gene in mammary epithelial cells (36) . It follows, therefore, that OPG in mammary tissue or in milk may exert some influence on such interactions.
If, as suggested by our gavage experiments in neonatal rats, milk OPG survives gastrointestinal passage and crosses the intestinal epithelium to be absorbed into the circulation, then it is tempting to speculate that it may modulate RANKL/RANK and TRAIL/TRAIL-R interactions, not only in the intestine lumen but also in underlying tissues. This being the case, the OPG-like activity of bovine milk not only may be exploited in products to regulate bone remodeling and immune responses in the infant, it may also provide a new and natural alternative therapy in instances of immune dysregulation and excessive bone resorption.
